
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corporation is positioned for a positive outlook due to its advancing orphan lung pipeline, which promises long-term diversification and growth opportunities beyond its established product offerings. The company is also implementing enhanced marketing and educational strategies aimed at healthcare professionals, which could further increase the uptake of its products, particularly Afrezza and Tyvaso DPI. With Tyvaso DPI gaining market share in pulmonary arterial hypertension and related conditions, along with the potential for increased royalty revenues, MannKind demonstrates substantial avenues for revenue generation and value creation.
Bears say
MannKind Corp's stock outlook appears negative due to growing competition and potential challenges in intellectual property protection, particularly following the approval of a competing product by SQ Innovation, which has led to a notable decline in MNKD's stock price. The company may also face share erosion and the necessity for price adjustments as it navigates potential setbacks related to trial outcomes, regulatory submissions, or adverse decisions that could impact the commercialization of its products. Additionally, while MannKind is developing innovative solutions, the presence of well-capitalized competitors with established products may further constrain its market position and pricing power.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares